Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cipla
Fish and Richardson
Deloitte
Johnson and Johnson
Farmers Insurance

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,470,720

« Back to Dashboard

Which drugs does patent 7,470,720 protect, and when does it expire?

Patent 7,470,720 protects HALAVEN and is included in one NDA.

This patent has forty-one patent family members in twenty-two countries.

Summary for Patent: 7,470,720
Title:Methods and compositions for use in treating cancer
Abstract:The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Towle; Murray J. (Auburn, NH)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:10/687,526
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,470,720
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;

Drugs Protected by US Patent 7,470,720

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,470,720

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 502932 ➤ Sign Up
Australia 2003284242 ➤ Sign Up
Australia 4573999 ➤ Sign Up
Australia 762998 ➤ Sign Up
Belgium 2011C028 ➤ Sign Up
Brazil 9911326 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Baxter
McKinsey
Fuji
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.